Who makes Vintafolide IV Infusion?

Vintafolide IV Infusion is developed by Endocyte.

What development phase is Vintafolide IV Infusion in?

Vintafolide IV Infusion is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Vintafolide IV Infusion

Endocyte · Phase 1 active Small molecule

At a glance

Generic name	Vintafolide IV Infusion
Sponsor	Endocyte
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) (PHASE3)
Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer (PHASE2)
Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) (PHASE2)
Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vintafolide IV Infusion CI brief — competitive landscape report
Vintafolide IV Infusion updates RSS · CI watch RSS
Endocyte portfolio CI